AYTU BIOPHARMA, INC Effective Income Tax Rate Reconciliation, Noncontrolling Interest Income (Loss), Amount
AYTU BIOPHARMA, INC (AYTU) reported Effective Income Tax Rate Reconciliation, Noncontrolling Interest Income (Loss), Amount of $167.00 thousand for the 12-month period ending 2020-06-30, per its 10-K filed 2020-10-06.
Discontinued › Expense Statement › Income Tax
us-gaap:IncomeTaxReconciliationMinorityInterestIncomeExpense · last filed 2020-10-06
- AYTU BIOPHARMA, INC effective income tax rate reconciliation, noncontrolling interest income (loss), amount for fiscal 2020 was $167.00K.
- AYTU BIOPHARMA, INC effective income tax rate reconciliation, noncontrolling interest income (loss), amount for fiscal 2019 was $0.00.
| Period end | Effective Income Tax Rate Reconciliation, Noncontrolling Interest Income (Loss), Amount 12 month |
|---|---|
| 2020-06-30 | $167.00K 10-K · filed 2020-10-06 |
| 2019-06-30 | $0.00 10-K · filed 2020-10-06 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| NextCure, Inc. (NXTC) | United States | $0.024B | -0.15 |
| TherapeuticsMD, Inc. (TXMD) | United States | $0.024B | -117.87 |
| ARTELO BIOSCIENCES, INC. (ARTL) | United States | $0.023B | |
| KYNTRA BIO, INC. (KYNB) | United States | $0.028B | 0.17 |
| Transcode Therapeutics, Inc. (RNAZ) | United States | $0.029B | -0.12 |
| Cocrystal Pharma, Inc. (COCP) | United States | $0.022B | |
| Hepion Pharmaceuticals, Inc. (HEPA) | United States | $0.029B | -0.62 |
| ATOSSA THERAPEUTICS, INC. (ATOS) | United States | $0.021B | -0.52 |
| IGC Pharma, Inc. (IGC) | United States | $0.029B | -5.98 |
| Neuphoria Therapeutics Inc. (NEUP) | United States | $0.020B | -1.77 |